Multidisciplinary wellness company focused on redefining traditional mental health and addiction treatments through novel psychedelics therapies Levitee Labs Inc. (CSE: LVT) (OTCMKTS: LVTTF) has announced formation of a Medical Advisory Board.
The newly established medical advisory board comprises of experts from across different fields including; psychedelics, chronic pain, compounding, neurology, drug development, policy, addiction and mental health.
Formation of the board which merges health professionals and other stake holders in the field signifies a key milestone for the company which is positioning itself as a leading national provider in comprehensive mental health and addiction treatments.
The company’s chief executive officer, Pouya Farmand, says formation of this board goes in line with the company signing agreements to purchase addiction focused clinics and pharmacies in Alberta and British Columbia.
“I’d like to formally welcome each new Medical Advisor, we are honored to have you as part of our team. Providing effective, easily accessible treatment options to the millions of people suffering from substance abuse disorder is the foundation of our strategy and I am confident in the contributions the Medical Advisory Board will make to meet all our goals by changing the existing paradigm. Our strategy is solid, and our team is unparalleled, a combination that points to a bright future where negative addiction stigmas are removed and instead of feeling hopeless, patients readily get the help and support they need to overcome their difficult disorders,” added the CEO.
